

Epsilon-V1-2

Cat. No.:	HY-P0154
CAS No.:	182683-50-7
Molecular Formula:	C ₃₇ H ₆₅ N ₉ O ₁₃
Molecular Weight:	843.96
Sequence Shortening:	EAVSLKPT
Target:	PKCε
Pathway:	Epigenetics; TGF-beta/Smad
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Epsilon-V1-2 (ε-V1-2), a PKCε-derived peptide, is a selective PKCε inhibitor. Epsilon-V1-2 inhibits the translocation of PKCε, but not α-, β-, and δPKC ^[1] .								
IC₅₀ & Target	PKCε								
In Vitro	<p>Epsilon-V1-2 (ε-V1-2), a PKCε-derived peptide containing the site for its specific receptor for activated C kinase (RACK), inhibits translocation of PKCε and reduces insulin response to glucose^[1].</p> <p>Epsilon-V1-2 (ε-V1-2; 1 μM, 24 hours) treatment significantly inhibits Oleic acid (OA)-induced connexin 43 (Cx43) Ser368 phosphorylation and prevents OA-induced gap junction disassembly in cardiomyocytes^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>Epsilon-V1-2 (20 mg/kg/day; osmotic pumps; daily; for 4 weeks) treatment significantly improves the beating score in a murine heterotopic transplantation model. Epsilon-V1-2 reduces infiltration of macrophages and T cells into the cardiac grafts, and decreases parenchymal fibrosis. Epsilon-V1-2 treatment almost abolishes the rise in pro-fibrotic cytokine, TGF-β and monocyte recruiting chemokine MCP-1 levels^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>C57BL/6J mice transplanted the hearts of FVB mice^[3]</td> </tr> <tr> <td>Dosage:</td> <td>20 mg/kg/day</td> </tr> <tr> <td>Administration:</td> <td>0.1 mL osmotic pumps implanted subcutaneously; daily; for 4 weeks</td> </tr> <tr> <td>Result:</td> <td>Significantly improved the beating score throughout the treatment.</td> </tr> </table>	Animal Model:	C57BL/6J mice transplanted the hearts of FVB mice ^[3]	Dosage:	20 mg/kg/day	Administration:	0.1 mL osmotic pumps implanted subcutaneously; daily; for 4 weeks	Result:	Significantly improved the beating score throughout the treatment.
Animal Model:	C57BL/6J mice transplanted the hearts of FVB mice ^[3]								
Dosage:	20 mg/kg/day								
Administration:	0.1 mL osmotic pumps implanted subcutaneously; daily; for 4 weeks								
Result:	Significantly improved the beating score throughout the treatment.								

REFERENCES

- [1]. M Yedovitzky, et al. Translocation inhibitors define specificity of protein kinase C isoenzymes in pancreatic beta-cells. *J Biol Chem.* 1997 Jan 17;272(3):1417-20.
- [2]. Yuahn-Sieh Huang, et al. Mechanism of oleic acid-induced gap junctional disassembly in rat cardiomyocytes. *J Mol Cell Cardiol.* 2004 Sep;37(3):755-66.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA